Sagent Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Sagent Pharmaceuticals Reports Second Quarter 2015 Financial Results
August 5, 2015 9:47 AM EDT
Piper Jaffray analyst David Amsellem lowered his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $32.00 (from $35.00) following Q2 results but maintained an Overweight rating.
Amsellem commented, "This morning, Sagent reported a 2Q15 net loss per share of ($0.01), compared to the Street EPS... More
August 4, 2015 11:17 AM EDT
RBC Capital upgraded Sagent Pharmaceuticals (NASDAQ: SGNT) from Sector Perform to Outperform.
For an analyst ratings summary and ratings history on Sagent Pharmaceuticals click here. For more ratings news on Sagent Pharmaceuticals click here.
Shares of Sagent Pharmaceuticals closed at $25.11 yesterday.
...
More
August 4, 2015 8:54 AM EDT
Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q2 EPS of ($0.01), $0.06 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $83.28 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.
...
More
